Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events. Gilead Sciences, incorporated on 22nd June 1987, and headquartered in Foster City, CA, is a biopharmaceutical company that discovers, develops and commercialises ethical drugs. Traditionally, the company has predominantly developed treatments for life-threatening infectious diseases, however, in 2006, Gilead expanded its research, development and commercial focus to include respiratory and cardiopulmonary disease through the acquisition of two pharmaceutical companies.

Gilead attributes its recent success and growing revenue to strong global organisation and infrastructure. The company intends to continue investment in improving this infrastructure to facilitate ongoing growth in short- to medium-term. In 2006, Gilead undertook a strategic realignment of its international commericial organisation to better build, manage and expand its presence in new and existing markets. Gilead is analysing and restructuring the way it distributes products as well as enhancing its manufacturing capabilities in order to cope with growing demand for its products. The acquisition of Raylo Chemicals was a core component of this strategy.

The cost of funding corporate development opportunities (including three significant acquisitions in 2006), building infrastructure and meeting daily operating needs continued to be an area of management focus in 2006. During this fiscal period, Gilead achieved record sales, however, increased costs resulted in significant losses in operating and net income. For 2007, Gilead hopes to maintain sales growth whilst achieving a greater balance with corporate spending. The company also recognises its strong reliance on its corporate partners, and hopes to maintain strong working relationships especially with Roche, Bristol-Myers Squibb, Merck & Co and GlaxoSmithKline.

In addition to Gilead's various collaborations with other companies and research institutions, the company is seeking to add to its product portfolio through its own internal and clinical development programmes. The acquisitions of Myogen and Corus Pharma have significantly expanded the scope of Gilead's research efforts.

This new strategic analysis report Gilead: Performance, Products, Pipeline and Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. The report is updated on a quarterly basis. Buyers of the web edition receive quarterly reports for a year. Buyers of the print/pdf editions receive the latest version. All formats are the same price.